

CLAIMS

We claim:

1. A method for producing a decellularized tissue engineered construct comprising the steps of:
providing a tissue engineered construct; and
decellularizing the tissue engineered construct, thereby forming a decellularized tissue engineered construct.

2. The method of claim 1, wherein the providing step comprises producing a tissue engineered construct, and wherein producing a tissue engineered construct comprises the steps of:
contacting a substrate with a population of cells capable of adhering thereto, thereby forming a cell-seeded construct; and
maintaining the cell-seeded construct under conditions suitable for growth of the population of cells for a growth period to form a tissue engineered construct.

3. The method of claim 1, wherein the providing step comprises producing a tissue engineered construct, and wherein producing a tissue engineered construct comprises the steps of:
contacting a substrate with a first population of cells capable of adhering thereto, thereby forming a primary cell-seeded construct; and
maintaining the cell-seeded construct under conditions suitable for growth of the first population of cells for a first growth period to form a primary tissue engineered construct;
contacting the primary tissue engineered construct with a second population of cells, thereby forming a secondary cell-seeded construct; and
maintaining the secondary cell-seeded construct under conditions suitable for growth of the second population of cells for a second growth period.

4. The method of claim 2, wherein the contacting and maintaining steps are repeated alternately until a cell-seeded construct having desired properties is formed.

1
2 5. The method of claim 4, wherein the contacting step is repeated using a plurality of different
3 cell types.

4
5 6. The method of claim 2, wherein the substrate comprises a biocompatible material.

6
7 7. The method of claim 2, wherein the substrate comprises a porous material.

8
9 8. The method of claim 2, wherein the substrate comprises a collagen sponge.

10
11 9. The method of claim 2, wherein the substrate comprises a polymeric material.

12
13 10. The method of claim 2, wherein the substrate comprises a length of tubing.

14
15 11. The method of claim 10, wherein the length of tubing is coated.

16
17 12. The method of claim 2, wherein the substrate comprises a synthetic polymeric material.

18
19 13. The method of claim 12, wherein the synthetic polymeric material has a hydrophilic surface.

20
21 14. The method of claim 12, wherein the polymeric material comprises a polymer selected from
22 the group consisting of polyesters of hydroxycarboxylic acids, polyanhydrides of dicarboxylic
23 acids, and copolymers of hydroxy carboxylic acids and dicarboxylic acids.

24
25 15. The method of claim 2 wherein the substrate has an inner and outer surface, wherein the
26 inner surface of the substrate defines a lumen.

27
28 16. The method of claim 2 wherein the substrate comprises a flat surface.

29
30 17. The method of claim 2 wherein the substrate comprises a three-dimensional structure.

1
2 18. The method of claim 2, wherein a mechanical force is applied to the construct during the
3 growth period.

4
5 19. The method of claim 2, wherein a pulsatile stimulus is applied to the construct during the
6 growth period.

7
8 20. The method of claim 2, wherein pulsatile stretch is applied to the construct during the growth
9 period.

10
11 21. The method of claim 2, wherein the growth period is continued until the construct reaches a
12 predetermined thickness.

13
14 22. The method of claim 2, wherein the growth conditions are chosen to promote deposition of
15 extracellular matrix components.

16
17 23. The method of claim 2, wherein the cells are selected from the group consisting of: smooth
18 muscle cells, cardiac muscle cells, epithelial cells, endothelial cells, urothelial cells, fibroblasts,
19 myoblasts, chondrocytes, chondroblasts, osteoblasts, osteoclasts, hepatocytes, bile duct cells,
20 pancreatic islet cells, thyroid, parathyroid, adrenal, hypothalamic, pituitary, ovarian, testicular,
21 salivary gland cells, adipocytes, and precursor cells.

22
23 24. The method of claim 2, wherein the cells are neonatal cells.

24
25 25. The method of claim 2, wherein the population of cells comprises cells of at least two cell
26 types.

27
28 26. The method of claim 2, wherein the cells are human cells.

29
30 27. The method of claim 2, wherein the cells are porcine cells.

- 1
- 2 28. The method of claim 2, wherein the cells are tumor cells.
- 3
- 4 29. The method of claim 2, wherein the cells are genetically transformed cells.
- 5
- 6 30. The method of claim 1 or 2, wherein the decellularization step comprises:
- 7 incubating the construct in a processing solution, the processing solution extracting cells
- 8 from the construct.
- 9
- 10 31. The method of claim 30, wherein the processing solution comprises at least one component
- 11 selected from the list consisting of: a detergent, a hypotonic solution, an RNA nuclease, and a
- 12 DNA nuclease.
- 13
- 14 32. The method of claim 1 or 2, wherein at least 50% of the cells are removed in the
- 15 decellularization step.
- 16
- 17 33. The method of claim 1 or 2, wherein at least 60% of the cells are removed in the
- 18 decellularization step.
- 19
- 20 34. The method of claim 1 or 2, wherein at least 70% of the cells are removed in the
- 21 decellularization step.
- 22
- 23 35. The method of claim 1 or 2, wherein at least 80% of the cells are removed in the
- 24 decellularization step.
- 25
- 26 36. The method of claim 1 or 2, wherein at least 90% of the cells are removed in the
- 27 decellularization step.
- 28
- 29 37. The method of claim 1 or 2, wherein at least 95% of the cells are removed in the
- 30 decellularization step.

1
2 38. The method of claim 1 or 2, wherein at least 99% of the cells are removed in the
3 decellularization step.

4
5 39. The method of claim 1 or 2, wherein substantially all of the cells are removed in the
6 decellularization step.

7
8 40. The method of claim 2, further comprising the step of:
9 removing a portion of the substrate.

10
11 41. The method of claim 2, further comprising the step of:
12 removing substantially all of the substrate.

13
14 42. The method of claim 2, further comprising the step of:
15 applying a fluid shear to the decellularized construct, thereby removing a portion of the
16 substrate.

17
18 43. The method of claim 2, further comprising the step of:
19 applying a fluid shear to the decellularized construct, thereby removing substantially all
20 of the substrate.

21
22 44. The method of claim 2, further comprising the step of:
23 storing the decellularized tissue engineered construct.

24
25 45. The method of claim 44, further comprising the step of:
26 before storing the decellularized construct, pretreating the decellularized construct with
27 an agent selected to protect the decellularized construct during the storage process.

28
29 46. The method of claim 44, wherein the storing comprises cryopreservation.
30

1 47. The method of claim 46, wherein the decellularized construct comprises a proteinaceous
2 matrix, and wherein the storing step comprises:

3 incubating the construct in a cryoprotective solution and freezing at cooling rates such
4 that minimal functional damage occurs to the proteinaceous matrix of the construct to produce a
5 cryoprepared construct;

6 drying the cryoprepared construct under temperature and pressure conditions that permit
7 removal of water without substantial ice recrystallization or ultrastructural damage.

8
9 48. The method of claim 44, wherein the storing comprises drying.

10
11 49. The method of claim 44, further comprising the step of:

12 reconstituting the decellularized construct after storage.

13
14 50. The method of claim 49, wherein the reconstituting step comprises:

15 incubating the decellularized construct in a rehydration solution, the rehydration solution
16 reducing osmotic, hypoxic, autolytic, or proteolytic damage.

17
18 51. The method of claim 49, wherein the reconstituting step comprises:

19 incubating the decellularized construct in a rehydration solution, the rehydration solution
20 reducing microbial contamination.

21
22 52. The method of claim 44, further comprising the step of:

23 treating the decellularized construct with a biologically active agent.

24
25 53. The method of claim 52, wherein the biologically active agent is selected to stimulate
26 recellularization of the construct.

27
28 54. The method of claim 52, wherein the biologically active agent is selected from the group
29 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
30 thrombomodulators, antibiotics, and agents that augment hemocompatibility.

1
2 55. The method of claim 1 or 2, further comprising the step of:

3 subjecting the decellularized construct to further tissue engineering.
4

5 56. The method of claim 1, wherein providing a tissue engineered construct comprises:

6 purchasing a tissue engineered construct.
7

8 57. The method of claim 1, wherein providing a tissue engineered construct comprises providing

9 a tissue engineered construct that has been produced primarily by growth *in vitro*.
10

11 58. The method of claim 1, wherein providing a tissue engineered construct comprises providing

12 a tissue engineered construct that has been produced at least in part by growth *in vivo*.
13

14 59. A method for treating a subject suffering from tissue damage or loss comprising:

15 producing a decellularized construct according to the method of claim 1 or 2; and

16 implanting the decellularized construct into a subject in need thereof.
17

18 60. The method of claim 59, wherein the implanting step comprises supplementing or replacing a
19 blood vessel of the subject.
20

21 61. The method of claim 59, wherein the implanting step comprises supplementing or replacing a

22 tissue of the subject, the tissue selected from the list consisting of: a heart valve, a muscle, a

23 joint, a ligament, a tendon, a bone, and an organ.
24

25 62. A method for producing an engineered construct comprising the steps of:

26 producing a tissue engineered construct;

27 decellularizing the tissue engineered construct, thereby forming a decellularized

28 construct;

29 contacting the decellularized construct with cells capable of adhering thereto, thereby

30 forming a cell-seeded decellularized construct; and

1 maintaining the cell-seeded decellularized construct for a growth period in an
2 environment suitable for growth of the cells to form an engineered construct.

3
4 63. The method of claim 62, wherein the producing step comprises:

5 contacting a substrate with a population of cells capable of adhering thereto, thereby
6 forming a cell-seeded construct; and

7 maintaining the cell-seeded construct under conditions suitable for growth of the
8 population of cells for a growth period to form a tissue engineered construct.

9
10 64. The method of claim 62, wherein the producing step comprises:

11 contacting a substrate with a first population of cells capable of adhering thereto, thereby
12 forming a primary cell-seeded construct; and

13 maintaining the cell-seeded construct under conditions suitable for growth of the first
14 population of cells for a first growth period to form a primary tissue engineered construct;

15 contacting the primary tissue engineered construct with a second population of cells,
16 thereby forming a secondary cell-seeded construct; and

17 maintaining the secondary cell-seeded construct under conditions suitable for growth of
18 the second population of cells for a second growth period.

19
20 65. The method of claim 62, wherein the cells comprise human cells.

21
22 66. The method of claim 62, wherein the cells comprise genetically transformed cells.

23
24 67. The method of claim 62, wherein the cells are obtained by harvesting cells from a subject, the
25 subject being the intended recipient of the tissue engineered construct.

26
27 68. The method of claim 62, wherein the cells are selected from the group consisting of: smooth
28 muscle cells, cardiac muscle cells, epithelial cells, endothelial cells, urothelial cells, fibroblasts,
29 myoblasts, chondrocytes, chondroblasts, osteoblasts, osteoclasts, hepatocytes, bile duct cells,

pancreatic islet cells, thyroid, parathyroid, adrenal, hypothalamic, pituitary, ovarian, testicular, salivary gland cells, adipocytes, and precursor cells.

69. The method of claim 68, wherein the cells comprise cells of at least two different cell types.

70. The method of claim 63 or claim 64, further comprising the step of:
removing a portion of the substrate.

71. The method of claim 63 or claim 64, further comprising the step of:
removing substantially all of the substrate.

72. The method of claim 63 or claim 64, further comprising the step of:
applying a fluid shear to the decellularized construct, thereby removing a portion of the substrate.

73. The method of claim 63 or claim 64, further comprising the step of:
applying a fluid shear to the decellularized construct, thereby removing substantially all of the substrate.

74. The method of claim 62, further comprising the step of:
after decellularizing the tissue engineered construct to obtain a decellularized construct, storing the decellularized construct under conditions selected to preserve the construct.

75. The method of claim 74, further comprising the step of:
before storing the decellularized construct, pretreating the decellularized construct with an agent selected to protect the construct during the storage process.

76. The method of claim 74, wherein the storing comprises cryopreservation.

77. The method of claim 74, wherein the storing comprises drying.

1
2 78. The method of claim 74, further comprising the step of:

3 reconstituting the decellularized construct after storage.
4

5 79. The method of claim 78, further comprising the step of:

6 treating the decellularized construct with a biologically active agent.
7

8 80. The method of claim 79, wherein the biologically active agent is selected to stimulate
9 recellularization of the construct.
10

11 81. The method of claim 79, wherein the biologically active agent is selected from the group
12 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
13 thrombomodulators, antibiotics, and agents that augment hemocompatibility.
14

15 82. A method for producing a decellularized engineered native tissue comprising the steps of:
16 procuring a tissue harvested from an animal or human;
17 engineering the harvested tissue, thereby forming an engineered native tissue; and
18 decellularizing the engineered native tissue, thereby forming a decellularized engineered
19 native tissue.
20

21 83. The method of claim 82, wherein the engineering step comprises:

22 seeding the harvested native tissue with cells; and
23 maintaining the tissue under conditions suitable for growth of the cells for a growth
24 period.
25

26 84. The method of claim 82, wherein the engineering step comprises:

27 subjecting the harvested tissue to a mechanical force, the mechanical force selected to
28 enhance the properties of the tissue.
29

30 85. The method of claim 82, wherein the engineering step comprises:

1 subjecting the harvested tissue to an electrical stimulus.

2
3 86. The method of claim 82, wherein the engineering step comprises:
4 subjecting the harvested tissue to a pulsatile stimulus.

5
6 87. The method of claim 82, wherein the engineering step comprises:
7 treating the harvested tissue with a biologically active agent.

8
9 88. The method of claim 87, wherein the biologically active agent is selected from the list
10 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
11 thrombomodulators, antibiotics, and agents that augment hemocompatibility.

12
13 89. The method of claim 87, wherein the biologically active agent comprises:
14 a pharmaceutical composition.

15
16 90. The method of claim 82, wherein the harvested tissue comprises a blood vessel.

17
18 91. The method of claim 82, wherein the harvested tissue comprises a heart valve.

19
20 92. The method of claim 82, wherein the harvested tissue comprises an organ or a portion
21 thereof.

22
23 93. The method of claim 82, wherein the harvested tissue comprises a muscle.

24
25 94. The method of claim 82, further comprising the step of:
26 subjecting the decellularized engineered native tissue to further tissue engineering.

27
28 95. The method of claim 82, further comprising the step of:
29 seeding the decellularized engineered native tissue with cells.

1 96. The method of claim 95 wherein the cells are selected from the group consisting of: smooth
2 muscle cells, cardiac muscle cells, epithelial cells, endothelial cells, urothelial cells, fibroblasts,
3 myoblasts, chondrocytes, chondroblasts, osteoblasts, osteoclasts, hepatocytes, bile duct cells,
4 pancreatic islet cells, thyroid, parathyroid, adrenal, hypothalamic, pituitary, ovarian, testicular,
5 salivary gland cells, adipocytes, and precursor cells.

6
7 97. The method of claim 95, wherein the cells comprise cells of at least two different cell types.

8
9 98. The method of claim 95, wherein the cells comprise neonatal cells.

10
11 99. The method of claim 95, wherein the cells comprise human cells.

12
13 100. The method of claim 95, wherein the cells comprise genetically transformed cells.

14
15 101. A method for treating a subject suffering from tissue damage or loss comprising the steps
16 of:

17 producing an engineered, decellularized construct according to the method of claim 62;

18 and

19 implanting the tissue engineered construct into a subject in need thereof.

20
21 102. The method of claim 101, wherein the cells used in the final contacting step are obtained by
22 harvesting cells from the subject.

23
24 103. The method of claim 101, wherein the cells used in the final contacting step are obtained by
25 a method comprising the steps of:

26 harvesting cells from the subject; and

27 culturing the cells *in vitro* prior to seeding the decellularized construct.

28
29 104. The method of claim 101, wherein the implanting step comprises supplementing or
30 replacing a blood vessel of the subject.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

105. The method of claim 101, wherein the implanting step comprises supplementing or replacing a tissue of the subject, the tissue selected from the list consisting of: a heart valve, a muscle, a joint, a ligament, a tendon, a bone, and an organ.

106. The method of claim 101, further comprising the step of:
treating the engineered, decellularized construct with a biologically active agent before the implanting step, whereby the construct serves as a vehicle for delivery of the biologically active agent to the subject.

107. The method of claim 106, further comprising the step of:

1 treating the engineered, decellularized construct with a biologically active agent before
2 the implanting step, wherein the biologically active agent is selected to enhance recellularization
3 or vascularization of the construct after the implanting step.

4
5 108. The method of claim 106, wherein the biologically active agent comprises a pharmaceutical
6 composition.

7
8 109. The method of claim 106, wherein the biologically active agent is selected from the group
9 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
10 thrombomodulators, antibiotics, and agents that augment hemocompatibility.

11
12 110. An engineered tissue for use as a tissue engineering scaffold or for implanting into a subject
13 comprising:
14 a decellularized engineered native tissue.

15
16 111. The engineered tissue of claim 110, wherein at least 50% of the cells are removed from the
17 decellularized engineered native tissue by decellularization.

18
19 112. The engineered tissue of claim 110, wherein at least 60% of the cells are removed from the
20 decellularized engineered native tissue by decellularization.

21
22 113. The engineered tissue of claim 110, wherein at least 70% of the cells are removed from the
23 decellularized engineered native tissue by decellularization.

24
25 114. The engineered tissue of claim 110, wherein at least 80% of the cells are removed from the
26 decellularized engineered native tissue by decellularization.

27
28 115. The engineered tissue of claim 110, wherein at least 90% of the cells are removed from the
29 decellularized engineered native tissue by decellularization.

1 116. The engineered tissue of claim 110, wherein at least 95% of the cells are removed from the
2 decellularized engineered native tissue by decellularization.

3
4 117. The engineered tissue of claim 110, wherein at least 99% of the cells are removed from the
5 decellularized engineered native tissue by decellularization.

6
7 118. The engineered tissue of claim 110, further comprising a biologically active agent.

8
9 119. The engineered tissue of claim 110, wherein the biologically active agent is selected to
10 enhance recellularization or vascularization of the tissue engineered construct.

11
12 120. The engineered tissue of claim 110, wherein the biologically active agent comprises a
13 pharmaceutical composition.

14
15 121. The engineered tissue of claim 110, wherein the biologically active agent is selected from
16 the group consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
17 thrombomodulators, antibiotics, and agents that augment hemocompatibility.

18
19 122. The engineered tissue of claim 110, wherein the engineered native tissue comprises native
20 tissue that has been subjected to a mechanical force after removal from an animal or human
21 source, wherein the mechanical force is selected to enhance the properties of the tissue.

22
23 123. The engineered tissue of claim 110, wherein the engineered native tissue comprises native
24 tissue that has been subjected to electrical stimulation after removal from an animal or human
25 source.

26
27 124. The engineered tissue of claim 110, wherein the engineered native tissue comprises native
28 tissue that has been treated with a growth factor after removal from an animal or human source.

1 125. The engineered tissue of claim 110, wherein the engineered native tissue comprises native
2 tissue that has been exposed to serum after removal from an animal or human source.

3
4 126. The engineered tissue of claim 110, wherein the engineered native tissue comprises native
5 tissue that has been exposed to a pulsatile stimulus after removal from an animal or human
6 source.

7
8 127. The engineered tissue of claim 110, further comprising:
9 a population of cells, wherein the decellularized engineered native tissue is seeded with
10 the population of cells after decellularization.

11
12 128. The engineered tissue of claim 127, wherein the decellularized engineered native tissue is
13 maintained under conditions suitable for growth of the cells for a growth period following
14 seeding.

15
16 129. The engineered tissue of claim 127, wherein the cells comprise human cells.

17
18 130. The engineered tissue of claim 127, wherein the cells comprise porcine cells.

19
20 131. The engineered tissue of claim 127, wherein the cells comprise neonatal cells.

21
22 132. A construct for use as a tissue engineering scaffold or for implanting into a subject
23 comprising:

24 a tissue engineered construct that has been subjected to decellularization.

25
26 133. The construct of claim 132, wherein the tissue engineered construct comprises a substrate
27 seeded with cells and maintained under conditions suitable for growth of the cells for a growth
28 period.

1 134. The construct of claim 133, wherein the growth period comprises a period of time sufficient
2 for formation of a tissue engineered construct having a predetermined thickness.

3
4 135. The construct of claim 133, wherein at least 50% of the cells are removed from the tissue
5 engineered construct by decellularization.

6
7 136. The construct of claim 133, wherein at least 60% of the cells are removed from the tissue
8 engineered construct by decellularization.

9
10 137. The construct of claim 133, wherein at least 70% of the cells are removed from the tissue
11 engineered construct by decellularization.

12
13 138. The construct of claim 133, wherein at least 80% of the cells are removed from the tissue
14 engineered construct by decellularization.

15
16 139. The construct of claim 133, wherein at least 90% of the cells are removed from the tissue
17 engineered construct by decellularization.

18
19 140. The construct of claim 133, wherein at least 95% of the cells are removed from the tissue
20 engineered construct by decellularization.

21
22 141. The construct of claim 133, wherein at least 99% of the cells are removed from the tissue
23 engineered construct by decellularization.

24
25 142. The construct of claim 132, further comprising a biologically active agent.

26
27 143. The construct of claim 132, wherein the biologically active agent is selected to enhance
28 recellularization or vascularization of the tissue engineered construct.

1 144. The construct of claim 132, wherein the biologically active agent comprises a
2 pharmaceutical composition.

3
4 145. The construct of claim 132, wherein the biologically active agent is selected from the group
5 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
6 thrombomodulators, antibiotics, and agents that augment hemocompatibility.

7
8 146. The construct of claim 132, wherein the tissue engineered construct comprises a tissue
9 engineered construct that has been subjected to a mechanical force during a growth period.

10
11 147. The construct of claim 132, wherein the tissue engineered construct comprises a tissue
12 engineered construct that has been subjected to a pulsatile stimulus during a first growth period.

13
14 148. The construct of claim 132, wherein the tissue engineered construct comprises a tissue
15 engineered construct that has been subjected to electrical stimulation during a first growth
16 period.

17
18 149. The construct of claim 132, wherein the tissue engineered construct comprises a tissue
19 engineered construct that has been treated with a growth factor during a first growth period.

20
21 150. The construct of claim 132, wherein the tissue engineered construct comprises a tissue
22 engineered construct that has been exposed to serum during a first growth period.

23
24 151. The construct of claim 133, wherein the substrate comprises a polymeric material.

25
26 152. The construct of claim 133, wherein the substrate comprises a length of tubing.

27
28 153. The construct of claim 133, wherein the length of tubing is coated.

29
30 154. The construct of claim 133, wherein the substrate comprises a synthetic polymeric material.

1
2 155. The construct of claim 133, wherein the polymeric material comprises a polymer selected
3 from the group consisting of polyesters of hydroxycarboxylic acids, polyanhydrides of
4 dicarboxylic acids, and copolymers of hydroxy carboxylic acids and dicarboxylic acids.

5
6 156. The construct of claim 133, wherein the substrate comprises a collagen sponge.

7
8 157. The construct of claim 133, wherein the substrate has an inner and outer surface, and
9 wherein the inner surface of the substrate defines a lumen.

10
11 158. The construct of claim 133, wherein the substrate comprises a flat surface.

12
13 159. The construct of claim 133, wherein the substrate comprises a three-dimensional structure.

14
15 160. The construct of claim 133, wherein the construct is treated so as to remove substantially all
16 of the substrate.

17
18 161. The construct of claim 133, wherein the cells are selected from the group consisting of:
19 smooth muscle cells, cardiac muscle cells, epithelial cells, endothelial cells, urothelial cells,
20 fibroblasts, myoblasts, chondrocytes, chondroblasts, osteoblasts, osteoclasts, hepatocytes, bile
21 duct cells, pancreatic islet cells, thyroid, parathyroid, adrenal, hypothalamic, pituitary, ovarian,
22 testicular, salivary gland cells, adipocytes, and precursor cells.

23
24 162. The construct of claim 133, wherein the cells comprise cells of at least two different cell
25 types.

26
27 163. The construct of claim 133, wherein the cells comprise neonatal cells.

28
29 164. The construct of claim 133, wherein the cells comprise human cells.

1 165. The construct of claim 133, wherein the cells comprise porcine cells.

3 166. The construct of claim 133, wherein the cells comprise tumor cells.

5 167. The construct of claim 133, wherein the cells comprise genetically transformed cells.

7 168. A method for treating a subject suffering from tissue damage or loss comprising:
8 implanting the construct of claim 132 into a subject in need thereof.

10 169. The method of claim 168, further comprising the step of:

11 treating the construct with a biologically active agent before the implanting step, whereby
12 the construct serves as a vehicle for delivery of the biologically active agent to the subject.

14 170. The method of claim 168, further comprising the step of:

15 treating the construct with a biologically active agent before the implanting step, whereby
16 the biologically active agent is selected to enhance recellularization or vascularization of the
17 construct after the implanting step.

19 171. The method of claim 168, wherein the biologically active agent comprises a pharmaceutical
20 composition.

22 172. The method of claim 168, wherein the biologically active agent is selected from the group
23 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
24 thrombomodulators, antibiotics, and agents that augment hemocompatibility.

26 173. The method of claim 168, wherein the implanting step comprises supplementing or
27 replacing a blood vessel of the subject.

1 174. The method of claim 168, wherein the implanting step comprises supplementing or
2 replacing a tissue of the subject, the tissue selected from the list consisting of: a heart valve, a
3 muscle, a joint, a ligament, a tendon, a bone, and an organ.

4
5 175. A method for treating a subject suffering from tissue damage or loss comprising:
6 implanting the engineered tissue of claim 110 into a subject in need thereof.

7
8 176. The method of claim 175, further comprising the step of:
9 treating the engineered tissue with a biologically active agent before the implanting step,
10 whereby the engineered tissue serves as a vehicle for delivery of the biologically active agent to
11 the subject.

12
13 177. The method of claim 175, further comprising the step of:
14 treating the engineered tissue with a biologically active agent before the implanting step,
15 whereby the biologically active agent is selected to enhance recellularization or vascularization
16 of the engineered tissue after the implanting step.

17
18 178. The method of claim 175, wherein the biologically active agent comprises a pharmaceutical
19 composition.

20
21 179. The method of claim 175, wherein the biologically active agent is selected from the group
22 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
23 thrombomodulators, antibiotics, and agents that augment hemocompatibility.

24
25 180. The method of claim 175, wherein the implanting step comprises supplementing or
26 replacing a blood vessel of the subject.

27
28 181. The method of claim 175, wherein the implanting step comprises supplementing or
29 replacing a tissue of the subject, the tissue selected from the list consisting of: a heart valve, a
30 muscle, a joint, a ligament, a tendon, a bone, and an organ.

1
2 182. A construct for use in tissue engineering or for implanting into a subject comprising:
3 a decellularized tissue engineered construct; and
4 a population of cells, wherein the decellularized tissue engineered construct is seeded
5 with the population of cells.
6

7 183. The construct of claim 182, wherein the decellularized tissue engineered construct
8 comprises a decellularized tissue engineered construct that has been subjected to a mechanical
9 force during a growth period.

10
11 184. The construct of claim 182, wherein the decellularized tissue engineered construct
12 comprises a decellularized tissue engineered construct that has been subjected to a pulsatile
13 stimulus during a growth period.
14

15 185. The construct of claim 182, wherein the decellularized tissue engineered construct
16 comprises a decellularized tissue engineered construct that has been subjected to electrical
17 stimulation during a growth period.
18

19 186. The construct of claim 182, wherein the decellularized tissue engineered construct
20 comprises a decellularized tissue engineered construct that has been treated with a growth factor
21 during a growth period.
22

23 187. The construct of claim 182, wherein the decellularized tissue engineered construct
24 comprises a decellularized tissue engineered construct that has been exposed to serum during a
25 growth period.
26

27 188. The construct of claim 182, wherein the decellularized tissue engineered construct
28 comprises a decellularized tissue engineered construct produced using human cells.
29

- 1 189. The construct of claim 182, wherein the decellularized tissue engineered construct
2 comprises a decellularized tissue engineered construct produced using neonatal cells.
3
- 4 190. The construct of claim 182, wherein the decellularized tissue engineered construct
5 comprises a decellularized tissue engineered construct produced using genetically transformed
6 cells.
7
- 8 191. The construct of claim 182, wherein the decellularized tissue engineered construct
9 comprises a decellularized tissue engineered construct produced using human cells.
10
- 11 192. The construct of claim 182, wherein the decellularized tissue engineered construct
12 comprises a decellularized tissue engineered construct produced using cells selected from the
13 group consisting of: smooth muscle cells, cardiac muscle cells, epithelial cells, endothelial cells,
14 urothelial cells, fibroblasts, myoblasts, chondrocytes, chondroblasts, osteoblasts, osteoclasts,
15 hepatocytes, bile duct cells, pancreatic islet cells, thyroid, parathyroid, adrenal, hypothalamic,
16 pituitary, ovarian, testicular, salivary gland cells, adipocytes, and precursor cells.
17
- 18 193. The tissue engineered construct of claim 182, wherein the cells comprise cells harvested
19 from an intended recipient of the construct.
20
- 21 194. The construct of claim 182, wherein the population of cells is cultured *in vitro* before the
22 decellularized tissue engineered construct is seeded therewith.
23
- 24 195. The construct of claim 182, wherein the population of cells is selected from the group
25 consisting of: smooth muscle cells, cardiac muscle cells, epithelial cells, endothelial cells,
26 urothelial cells, fibroblasts, myoblasts, chondrocytes, chondroblasts, osteoblasts, osteoclasts,
27 hepatocytes, bile duct cells, pancreatic islet cells, thyroid, parathyroid, adrenal, hypothalamic,
28 pituitary, ovarian, testicular, salivary gland cells, adipocytes, and precursor cells.
29

- 1 196. The construct of claim 182, wherein the population of cells comprises cells of at least two
2 different cell types.
3
- 4 197. The construct of claim 182, wherein the population of cells comprises neonatal cells.
5
- 6 198. The construct of claim 182, wherein the population of cells comprises human cells.
7
- 8 199. The construct of claim 182, wherein the decellularized tissue engineered construct is
9 maintained for growth period under growth conditions suitable for the growth of the population
10 of cells.
- 11 200. The construct of claim 182, wherein the decellularized tissue engineered construct
12 comprises a decellularized tissue engineered construct that has been subjected to a mechanical
13 force during a growth period.
14
- 15 201. The construct of claim 182, wherein the decellularized tissue engineered construct
16 comprises a decellularized tissue engineered construct that has been subjected to a pulsatile
17 stimulus during a growth period.
18
- 19 202. The construct of claim 182, wherein the decellularized tissue engineered construct
20 comprises a decellularized construct that has been subjected to electrical stimulation during a
21 growth period.
22
- 23 203. The construct of claim 182, wherein the decellularized tissue engineered construct
24 comprises a decellularized tissue engineered construct that has been treated with a growth factor
25 during a growth period.
26
- 27 204. The construct of claim 182, wherein the decellularized tissue engineered construct
28 comprises a decellularized tissue engineered construct that has been exposed to serum during a
29 growth period.
30

1
2 205. A method for treating a subject suffering from tissue damage or loss comprising:
3 implanting the construct of claim 182 into a subject in need thereof.
4

5 206. The method of claim 205, further comprising the step of:
6 treating the construct with a biologically active agent before the implanting step, whereby
7 the construct serves as a vehicle for delivery of the biologically active agent to the subject.
8

9 207. The method of claim 205, further comprising the step of:
10 treating the construct with a biologically active agent before the implanting step, whereby
11 the biologically active agent is selected to enhance recellularization or vascularization of the
12 construct after the implanting step.
13

14 208. The method of claim 205, wherein the biologically active agent comprises a pharmaceutical
15 composition.
16

17 209. The method of claim 205, wherein the biologically active agent is selected from the group
18 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
19 thrombomodulators, antibiotics, and agents that augment hemocompatibility.
20

21 210. The method of claim 205, wherein the implanting step comprises supplementing or
22 replacing a blood vessel of the subject.
23

24 211. The method of claim 205, wherein the implanting step comprises supplementing or
25 replacing a tissue of the subject, the tissue selected from the list consisting of: a heart valve, a
26 muscle, a joint, a ligament, a tendon, a bone, and an organ.
27

28 212. A method for treating a subject suffering from tissue damage or loss comprising:
29 implanting the construct of claim 199 into a subject in need thereof.
30

1 213. The method of claim 212, further comprising the step of:

2 treating the construct with a biologically active agent before the implanting step, whereby
3 the construct serves as a vehicle for delivery of the biologically active agent to the subject.
4

5 214. The method of claim 212, further comprising the step of:

6 treating the construct with a biologically active agent before the implanting step, whereby
7 the biologically active agent is selected to enhance recellularization or vascularization of the
8 construct after the implanting step.
9

10 215. The method of claim 212, wherein the biologically active agent comprises a pharmaceutical
11 composition.
12

13 216. The method of claim 212, wherein the biologically active agent is selected from the group
14 consisting of: growth factors, adhesion factors, soluble extracellular matrix proteins,
15 thrombomodulators, antibiotics, and agents that augment hemocompatibility.
16

17 217. The method of claim 212, wherein the implanting step comprises supplementing or
18 replacing a blood vessel of the subject.
19

20 218. The method of claim 212, wherein the implanting step comprises supplementing or
21 replacing a tissue of the subject, the tissue selected from the list consisting of: a heart valve, a
22 muscle, a joint, a ligament, a tendon, a bone, and an organ.
23